

Special Issue

Transformation of Multiple Myeloma into Extramedullary Myeloma or Plasma Cell Leukemia

Message from the Guest Editor

Multiple myeloma is the second most common hematological malignancy. It is characterized by malignant plasma cell infiltration of the bone marrow. Unfortunately, a subclone of these plasma cells may also migrate out of the bone marrow losing its dependence on the bone marrow microenvironment. Thus, multiple myeloma may transform into extramedullary myeloma (EM) (plasma cells infiltrate soft tissues, sometimes forming tumors) or plasma cell leukemia (PCL) (plasma cells migrate into peripheral blood). Both EM and PCL have unfavorable clinical outcomes. This Special Issue “Transformation of Multiple Myeloma into Extramedullary Myeloma or Plasma Cell Leukemia” aims to clarify the pathogenesis of EM and/or PCL, biomarkers of these diseases, early diagnosis options, translational research, and treatment options. We welcome original basic, translational, and molecular biology-based clinical research articles, as well as review articles, leading to an improvement in our understanding of both EM and PCL.

Guest Editor

Dr. Sabina Ševčíková

Babak Myeloma Group, Department of Pathological Physiology, Faculty of Medicine, Masaryk University, 625 00 Brno, Czech Republic

Deadline for manuscript submissions

closed (30 June 2022)



Biomedicines

an Open Access Journal
by MDPI

Impact Factor 3.9
CiteScore 6.8
Indexed in PubMed



mdpi.com/si/74745

Biomedicines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
biomedicines@mdpi.com

[mdpi.com/journal/
biomedicines](https://mdpi.com/journal/biomedicines)





Biomedicines

an Open Access Journal
by MDPI

Impact Factor 3.9
CiteScore 6.8
Indexed in PubMed



[mdpi.com/journal/
biomedicines](https://mdpi.com/journal/biomedicines)



About the Journal

Message from the Editor-in-Chief

Biomedicines (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

Editor-in-Chief

Prof. Dr. Felipe Fregni

1. Neuromodulation Center and Center for Clinical Research Learning, Spaulding Rehabilitation Hospital and Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA
2. Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, CAPus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Medicine (miscellaneous))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 17 days after submission; acceptance to publication is undertaken in 2.9 days (median values for papers published in this journal in the first half of 2025).